Inspire Pharmaceuticals (ISPH) Inactive 10-Q2007 Q2 Quarterly report

Filed: 9 Aug 07, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: accrue, accrued, add, affirmative, AmerisourceBergen, ANDA, anniversary, annum, Antitrust, argued, barred, buyer, buying, Catalent, characterized, Circuit, cohort, commercializeAzaSiteTM, consignment, convene, Cosmetic, deducted, deemed, depository, destruction, dismissed, dissolution, dividend, EITF, Eliason, employ, entirety, expend, expiredAzaSite, FIFO, footnote, forAzaSitein, front, Global, hand, HSR, incremental, involuntary, IX, Jonathan, Judge, labor, lawfully, Leff, line, load, losing, lostElestat, lt, Magistrate, McKesson, member, Nasdaq, nonrefundable, ofAzaSitebeginning, ofAzaSitein, ofAzaSitewhen, ofElestatandRestasisfor, older, ourAzaSite, ourAzaSitelaunch, ourElestat, outlay, overhead, owner, perspective, persuasive, physical, prejudice, prepaid, prepay, prepayment, processed, processing, promoteAzaSite, promoteElestatto, rata, ratify, ratio, reborrowed, reclassified, recruiting, redeem, redeemable, redeemed, redemption, referred, repaid, Restasisand, Restasisare, retail, revert, SAR, sector, sellAzaSite, seller, sheet, shipment, simultaneously, Sirion, split, Standstill, strength, subscription, supplemental, Task, temporary, theft, thereon, transaction, unmarketable, unpaid, vast, waive, Warburg, whichAzaSite, whichElestat, wholesaler, wholesaling, winding, withAzaSite

Removed: continuation, fill, filled, growth, inspect, methodology, negotiated, platelet, prescribed, promoteElestat, realizing, Recalling, targeting, undergo, unpartnered

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ISPH similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Inspire Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2007, as filed with the Securities and Exchange Commission (the “Report”), I, Christy L. Shaffer, President & Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 9, 2007

/s/ Christy L. Shaffer

Christy L. Shaffer

President & Chief Executive Officer

(principal executive officer)